NIH Reporter #5R35CA263922-04

NCI Research Project on Nuclear Epigenetic and Metabolic Pathways in Cancer

This opportunity from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), focuses on advancing cancer research through the study of nuclear epigenetic and metabolic pathways. - Government Buyer: - National Cancer Institute (NCI), National Institutes of Health (NIH) - Awardee: - University of Pennsylvania - Products/Services Requested: - Multidisciplinary research project titled 'Interaction between nuclear epigenetic and metabolic pathways in cancer' - Focus areas include chromatin biology, gene expression, nuclear metabolism, and identification of new therapeutic targets (e.g., ACSS2 inhibitors) - Unique/Notable Requirements: - Research must bridge cancer biology, epigenetics, and metabolism - Emphasis on novel epigenetic regulation and the nuclear metabolic-epigenetic axis - Proposals must align with project goals and be submitted by the response deadline - No specific OEMs, vendors, products, or part numbers are mentioned - Award amount is $974,274, covering direct and indirect costs - Period of performance spans seven years

Description

This project aims to investigate the intersection of epigenetic regulation and nuclear metabolism in cancer, focusing on mechanisms involving chromatin, gene expression, and metabolic pathways. The research will explore novel epigenetic regulation, the role of nuclear speckles, and the nuclear metabolic-epigenetic axis, with the goal of identifying new therapeutic targets such as the inhibitor targeting ACSS2. The multidisciplinary project bridges cancer biology, epigenetics, and metabolism, aiming to uncover novel mechanisms involved in tumor formation and potential therapeutic strategies. The project duration is from September 1, 2022 to August 31, 2029.

View original listing